Form 4 for CELU Celularity Inc
Accepted 2024-02-21 00:00:00 ET · period of report 2024-02-16 · accession 0001493152-24-007487 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-21 | 2024-02-17 | CELU | Kilcoyne Adrian | Chief Medical Off | F - Tax | $0.43 | -52.8K | 1.12M | -4% | -$22.7K |
| D | 2024-02-21 | 2024-02-16 | CELU | Kilcoyne Adrian | Chief Medical Off | A - Grant | $0.00 | +205.2K | 205.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-02-17 | F | D | 52,762 | $0.43 | 1,122,238 | D | — | — | (F1) Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale. (F2) Reflects shares underlying RSUs subject to vesting. |
| 2 | Derivative | Stock Option Grant (Right to Buy) | 2024-02-16 | A | A | 205,213 | $0.00 | 205,213 | D | $0.43 · — to 2034-02-15 | 205,213 Class A Common Stock | (F3) The option was granted pursuant to the 2021 Plan. The shares underlying such option will vest in equal quarterly installments during 2024 such that 25% of the option will vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service with the Issuer through each such date. |